Benefit-risk assessment of new and emerging treatments for hepatitis C: Focus on simeprevir and sofosbuvir

Drug, Healthcare and Patient Safety

Volumn 6, Issue 1, 2014, Pages 37-45

  Gaetano, John N ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

HCV genotype; Liver disease; Treatment na ve and treatment experienced

Indexed keywords

ABT 267; ABT 333; ABT 450; DACLATASVIR; LEDIPASVIR; NEW DRUG; PEGINTERFERON ALPHA; PLACEBO; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; UNCLASSIFIED DRUG;

ANEMIA; ANTIVIRAL ACTIVITY; COMBINATION CHEMOTHERAPY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; GENOTYPE; GOLD STANDARD; HEADACHE; HEPATITIS C; HUMAN; INSOMNIA; JAUNDICE; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR DEPRESSION; NAUSEA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 84897373608     PISSN: None     EISSN: 11791365     Source Type: Book Series    
DOI: 10.2147/DHPS.S43304     Document Type: Review

References (37)

1. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int. 2011;31(8):1090-1101.
2. Institute of Medicine Report Brief. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: National Academy of Sciences; 2010. Available from: http://www.iom.edu/viralhepatitis. Accessed January 10, 2014.
3. Asrani SK, Larson JJ, Yawn B, Therneau TM, Kim WR. Underestimation of liver-related mortality in the United States. Gastroenterology. 2013;145(2):375-382, e1-e2.
4. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859-1861.
5. Ward JW, Lok AS, Thomas DL, El-Serag HB, Kim WR. Report on a single-topic conference on "Chronic viral hepatitis - strategies to improve effectiveness of screening and treatment". Hepatology. 2012;55(1):307-315.
6. Lee G, Piper DE, Wang Z, et al. Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases. J Mol Biol. 2006;357(4): 1051-1057.
7. Biswal BK, Wang M, Cherney MM, et al. Non-nucleoside inhibitors binding to hepatitis C virus NS5B polymerase reveal a novel mechanism of inhibition. J Mol Biol. 2006;361(1):33-45.
8. INCIVEK® (telaprevir) [package insert]. Cambridge, MA: Vertex Pharmaceuticals Incorporated; 2013.
9. Poordad F, McCone J Jr, Bacon BR, et al; SPRINT-2 Investigators. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195-1206.
10. Bacon BR, Gordon SC, Lawitz E, et al; HCV RESPOND-2 Investigators. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207-1217.
11. Jacobson IM, McHutchison JG, Dusheiko G, et al; ADVANCE Study Team. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405-2416.
12. Sherman KE, Flamm SL, Afdhal NH, et al. Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study. AASLD 2010: 61st Annual Meeting for the American Association for the Study of Liver Disease; October 29-November 2, 2010; Boston, MA. Hepatology. 2010;52(4):401A-402A.
13. Gaetano JN, Reau N. Hepatitis C: management of side effects in the era of direct-acting antivirals. Curr Gastroenterol Rep. 2013; 15(1):305.
14. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF, Weber PC. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat Struct Biol. 1999;6(10):937-943.
15. Ali S, Leveque V, Le Pogam S, et al. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479. Antimicrob Agents Chemother. 2008;52(12):4356-4369.
16. Powdrill MH, Bernatchez JA, Götte M. Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B. Viruses. 2010;2(10):2169-2195.
17. Gao M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr Opin Virol. 2013;3(5):514-520.
18. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology. 2013;58(6): 1918-1929.
19. Jacobson I, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial. The International Liver Congress™ 2013, 48th Annual Meeting of the European Association for the Study of the Liver; April 24-28, 2013; Amsterdam, The Netherlands. J Hepatol Suppl. 2013;58(Suppl 1): S574.
20. Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment naive patients: results from QUEST-2, a phase III trial. The International Liver Congress™ 2013, 48th Annual Meeting of the European Association for the Study of the Liver; April 24-28, 2013; Amsterdam, The Netherlands. J Hepatol Suppl. 2013;58(Suppl 1): S568.
21. Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: efficacy in difficult-to-treat patient sub-populations in the QUEST 1 and 2 phase III trials. AASLD 2013: 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2013; November 1-5, 2013; Washington, DC. Hepatology. 2013;58(S1):756A-757A.
22. Lawitz E, Forns X, Zeuzem S, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV Genotype 1 Infection in patients who relapsed after previous interferon-based therapy: results from PROMISE, a Phase III trial. Digestive Disease Week 2013; May 18-21, 2013; Orlando, FL. Gastroenterology. 2013;144(5 Suppl 1): S-151.
23. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir (TMC435) with peg-interferon α-2a/ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: efficacy and safety in patient sub-populations in the PROMISE phase III trial. AASLD 2013: 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2013; November 1-5, 2013; Washington, DC. Hepatology. 2013;58(S1):737A-738A.
24. Bryden PA, Quigley JM, Padhiar A, Cerri K, Scott DA. The relative efficacy and safety of simeprevir-based triple therapy compared to boceprevir and telaprevir in treatment naïve patients chronically infected with genotype-1 hepatitis C virus: Bayesian network meta-analyses. AASLD 2013: 64th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2013; November 1-5, 2013; Washington, DC. Hepatology. 2013;58(S1):756A.
25. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381(9883):2100-2107.
26. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013;310(8):804-811.
27. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013;13(5):401-408.
28. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20): 1878-1887.
29. Jacobson IM, Gordon SC, Kowdley KV, et al; POSITRON Study; FUSION Study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-1877.
30. Antiviral Drugs Advisory Committee Meeting Briefing Document. Sofosbuvir for Treatment of Chronic Hepatitis C Infection. Foster City, CA: Gilead Sciences, Inc.; 2013:91-94. Available from: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/antiviraldrugsadvisorycommittee/ucm371877.pdf. Accessed March 1, 2014.
31. Lawitz E, Ghalib R, Rodriguez-Torres M, Younossi Z, Corregidor A, Jacobson I. COSMOS Study: SVR4 results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 null responders. 20th Conference on Retroviruses and Opportunistic Infections (CROI); March 3-6, 2013; Atlanta, GA.
32. Sulkowski MS Gardiner DF, Rodriguez-Torres M, et al; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211-221.
33. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet. 2014;383(9916):515-523.
34. Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med. 2014; 370(3):222-232.
35. Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: Is it worth it? Hepatology. 2014.
36. Transplant Living. Costs [homepage on the Internet]. Richmond, VA: United Network for Organ Sharing; 2014. Available from: http://www.transplantliving.org/before-the-transplant/financing-a-transplant/the-costs/. Accessed February 20, 2014.
37. National Digestive Diseases Information Clearinghouse (NDDIC). Liver Transplantation [homepage on the Internet]. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases. Available from: http://www.digestive.niddk.nih.gov/ddiseases/pubs/livertransplant. Accessed February 20, 2014.